Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
CD30 inhibitor
DRUG CLASS:
CD30 inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
AFM13 (3)
AFM13/AB-101 (1)
CD30 biAb-AATC (0)
GEN3017 (0)
AFM13 (3)
AFM13/AB-101 (1)
CD30 biAb-AATC (0)
GEN3017 (0)
›
Associations
(4)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL (LuminICE-203) (NCT05883449)
Phase 2
Affimed GmbH
Affimed GmbH
Recruiting
Phase 2
Affimed GmbH
Recruiting
Last update posted :
05/27/2024
Initiation :
10/10/2023
Primary completion :
04/30/2026
Completion :
11/30/2027
ALK • TNFRSF8
|
ALK positive • TNFRSF8 positive • ALK negative
|
cyclophosphamide • fludarabine IV • acimtamig (AFM13) • AFM13/AB-101 • AlloNK (GCC4001)
Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma (NCT04134325)
Phase 1
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
Recruiting
Phase 1
UNC Lineberger Comprehensive Cancer Center
Recruiting
Last update posted :
04/23/2024
Initiation :
09/01/2019
Primary completion :
04/01/2025
Completion :
07/07/2037
TNFRSF8 • CCR4
|
Keytruda (pembrolizumab) • Opdivo (nivolumab)
Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas (NCT04074746)
Phase 1/2
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Active, not recruiting
Phase 1/2
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
04/18/2024
Initiation :
07/18/2020
Primary completion :
04/15/2025
Completion :
04/15/2025
TNFRSF8
|
TNFRSF8 positive
|
cyclophosphamide • fludarabine IV • acimtamig (AFM13) • cyclophosphamide intravenous
CD30biAb-AATC for CD30+ Malignancies (NCT05544968)
Phase 1/2
Medical College of Wisconsin
Medical College of Wisconsin
Not yet recruiting
Phase 1/2
Medical College of Wisconsin
Not yet recruiting
Last update posted :
03/22/2024
Initiation :
12/01/2024
Primary completion :
01/01/2027
Completion :
01/01/2027
TNFRSF8
|
TNFRSF8 expression
|
CD30 biAb-AATC
Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT) (NCT04101331)
Phase 2
Affimed GmbH
Affimed GmbH
Completed
Phase 2
Affimed GmbH
Completed
Last update posted :
02/02/2024
Initiation :
11/13/2019
Primary completion :
05/11/2022
Completion :
01/11/2024
TNFRSF8
|
TNFRSF8 positive
|
acimtamig (AFM13)
AFM13 in Relapsed/Refractory Cutaneous Lymphomas (NCT03192202)
Phase 1/2
Ahmed Sawas
Ahmed Sawas
Completed
Phase 1/2
Ahmed Sawas
Completed
Last update posted :
07/20/2023
Initiation :
07/17/2017
Primary completion :
04/01/2020
Completion :
04/01/2020
TNFRSF8
|
TNFRSF8 positive
|
acimtamig (AFM13)
GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma (NCT02321592)
Phase 2
University of Cologne
University of Cologne
Completed
Phase 2
University of Cologne
Completed
Last update posted :
11/13/2020
Initiation :
05/01/2015
Primary completion :
11/01/2019
Completion :
07/01/2020
PD-L1
|
acimtamig (AFM13)
Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (KEYNOTE-206) (NCT02665650)
Phase 1b
Affimed GmbH
Affimed GmbH
Completed
Phase 1b
Affimed GmbH
Completed
Last update posted :
05/16/2019
Initiation :
05/01/2016
Primary completion :
01/01/2019
Completion :
03/01/2019
TNFRSF8
|
Keytruda (pembrolizumab) • acimtamig (AFM13)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login